Quick Answer
Aclaris Therapeutics, Inc. reported Cash and Equivalents of $19.96 million for fiscal year 2025.
Aclaris Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $19.96M | -18.8% |
| 2024 | $24.57M | -38.4% |
| 2023 | $39.88M | -11.9% |
| 2022 | $45.28M | +65.6% |
| 2021 | $27.35M | +24.0% |
| 2020 | $22.06M | -35.5% |
| 2019 | $34.19M | +69.2% |
| 2017 | $20.20M | -33.0% |
| 2016 | $30.17M | +206.3% |
| 2015 | $9.85M | -8.4% |
| 2014 | $10.76M | +12.2% |
| 2013 | $9.59M | -49.7% |
| 2012 | $19.04M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.26M | -47.0% | -0.6% |
| June 30, 2025 | $25.40M | +11.2% | -16.3% |
| March 31, 2025 | $30.36M | -15.3% | +23.6% |
| December 31, 2024 | $24.57M | -38.4% | -48.4% |
| September 30, 2024 | $47.65M | +22.1% | +108.7% |
| June 30, 2024 | $22.83M | -26.7% | -36.3% |
| March 31, 2024 | $35.84M | -19.9% | -10.1% |
| December 31, 2023 | $39.88M | -11.9% | +2.1% |
- Aclaris Therapeutics, Inc. showed a decrease of -18.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Aclaris Therapeutics, Inc.’s cash and equivalents has grown by 4.8% (from $19.04 million to $19.96 million).
- The most recent figure is from Aclaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: